Novadaq Technologies (NVDQ): Notes From Analyst Day - Wedbush
- Top 10 News for 12/2: Crude Rips on OPEC Cut; Starbucks' Schultz Steps Down; Nonfarm Payrolls Flat in Nov.
- Unemployment Rate Drops to 4.6%
- Bond yields slip on U.S. jobs data, euro steady before Italy vote
- Alibaba (BABA) Founder Jack Ma Discuss Plans to Retire; 'I Don't Want to Die at the Office'
- Starbucks Coffee (SBUX) CEO Howard Schultz to Step Down, Appointed Executive Chairman; Kevin Johnson New CEO
Get instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here.
Wedbush analyst, Tao Levy, reiterated his Outperform rating on shares of Novadaq Technologies (NASDAQ: NVDQ) after attending the company's Annual Analyst Meeting in NYC. Management used the event as a forum to discuss the company’s numerous growth opportunities, highlight the latest clinical evidence in support of broader adoption of SPY fluorescence technology, and introduce investors to some potential business model adjustments designed to ensure that it can grow revenues at 30% or greater y/y and reach cash flow breakeven in 1Q18.
The analyst found the in depth discussion on the lymphatics opportunity very interesting and believes that an easier way to identify lymph nodes is of significant interest to the minimally invasive surgeon community. In order to obtain FDA approval for the use of Pinpoint + ICG to help identify lymph nodes in women with uterine and cervical malignancies, Novadaq is enrolling patients in its FILM clinical trial. Approximately 70 women have been enrolled in the study (out of 150), which is expected to be completed in 1Q17. Thus far, management has not provided many details on the regulatory pathway, as it deems this information a competitive advantage.
No change to the price target of $17.
Shares of Novadaq Technologies closed at $8.88 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Jefferies Cuts Price Target on Kroger (KR) to $30 Following 3Q and Guidance
- FBR Capital Cuts Price Target on Express (EXPR) Following 3Q EPS Miss
- Jefferies Cuts Price Target on Dollar General (DG) Following 3Q
Create E-mail Alert Related CategoriesAnalyst Comments, Management Comments
Related EntitiesTao Levy
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!